Novel Coronavirus (COVID-19) Outbreak: Hope and Search for Effective Therapeutic Agent

Author(s): Saurabh Kumar*

Journal Name: Letters in Drug Design & Discovery

Volume 17 , Issue 8 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Novel Coronavirus (COVID-19), respiratory diseases and a major threat to mankind is spreading at an unstoppable rate affecting almost every part of the world with Europe being the most affected continent. Originated from China in December 2019 with sequence homology similar to SARS having a high rate of mutation has created a global pandemic with no effective therapy available.

Objective: This editorial summarizes the list of potential antiviral drugs or other effective therapy that is in the clinical trial.

Methods: The literature search is based on recent publications (year, 2020) available on PubMed and drug/therapy registered on the ClinicalTrial.gov portal.

Results: Hydroxychloroquine, tocilizumab, lopinavir/ritonavir, remdesivir, and convalescent plasma are some of the most common drug/therapy that has come as a hope against COVID-19.

Conclusion: In view of the current COVID-19 situation, more rigorous efforts are needed. Drugs with better outcomes need more exploration.

Keywords: COVID-19, pandemic, hydroxychloroquine, antiviral, clinical trial, drugs.

[1]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949]
[2]
Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020.
[http://dx.doi.org/110.1056/NEJMoa2007016]
[3]
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14(1): 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012]
[4]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. 2020. N Engl J Med 2020.
[http://dx.doi.org/10.1056/NEJMoa2001282]
[5]
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020.
[http://dx.doi.org/10.1073/pnas.2004168117]
[6]
Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020.
[http://dx.doi.org/10.1001/jama.2020.4783]
[7]
Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020.
[http://dx.doi.org/10.1101/2020.03.17.20037432]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 8
Year: 2020
Page: [940 - 942]
Pages: 3
DOI: 10.2174/1570180817999200612095513

Article Metrics

PDF: 48
HTML: 2